230 related articles for article (PubMed ID: 17652844)
21. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial.
Beer S; Aschbacher B; Manoglou D; Gamper E; Kool J; Kesselring J
Mult Scler; 2008 Mar; 14(2):231-6. PubMed ID: 17942510
[TBL] [Abstract][Full Text] [Related]
22. Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS.
Muraro PA; Uccelli A
Results Probl Cell Differ; 2010; 51():237-57. PubMed ID: 19513637
[TBL] [Abstract][Full Text] [Related]
23. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis.
Kastrinaki MC; Sidiropoulos P; Roche S; Ringe J; Lehmann S; Kritikos H; Vlahava VM; Delorme B; Eliopoulos GD; Jorgensen C; Charbord P; Häupl T; Boumpas DT; Papadaki HA
Ann Rheum Dis; 2008 Jun; 67(6):741-9. PubMed ID: 17921184
[TBL] [Abstract][Full Text] [Related]
24. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
[TBL] [Abstract][Full Text] [Related]
25. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
[TBL] [Abstract][Full Text] [Related]
26. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
[TBL] [Abstract][Full Text] [Related]
27. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy.
Pérez-Ilzarbe M; Díez-Campelo M; Aranda P; Tabera S; Lopez T; del Cañizo C; Merino J; Moreno C; Andreu EJ; Prósper F; Pérez-Simón JA
Transfusion; 2009 Sep; 49(9):1901-10. PubMed ID: 19497059
[TBL] [Abstract][Full Text] [Related]
29. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
[TBL] [Abstract][Full Text] [Related]
30. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.
Deda H; Inci MC; Kürekçi AE; Sav A; Kayihan K; Ozgün E; Ustünsoy GE; Kocabay S
Cytotherapy; 2009; 11(1):18-25. PubMed ID: 19012065
[TBL] [Abstract][Full Text] [Related]
31. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power.
Crisostomo PR; Markel TA; Wang M; Lahm T; Lillemoe KD; Meldrum DR
Surgery; 2007 Aug; 142(2):215-21. PubMed ID: 17689688
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke.
Dharmasaroja P
J Clin Neurosci; 2009 Jan; 16(1):12-20. PubMed ID: 19017556
[TBL] [Abstract][Full Text] [Related]
33. Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: comparisons with bone marrow mesenchymal stem cells and with fetal bovine serum.
Nimura A; Muneta T; Koga H; Mochizuki T; Suzuki K; Makino H; Umezawa A; Sekiya I
Arthritis Rheum; 2008 Feb; 58(2):501-10. PubMed ID: 18240254
[TBL] [Abstract][Full Text] [Related]
34. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment.
Mazzanti B; Aldinucci A; Biagioli T; Barilaro A; Urbani S; Dal Pozzo S; Amato MP; Siracusa G; Crescioli C; Manuelli C; Bosi A; Saccardi R; Massacesi L; Ballerini C
J Neuroimmunol; 2008 Aug; 199(1-2):142-50. PubMed ID: 18562015
[TBL] [Abstract][Full Text] [Related]
35. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
Fagius J; Lundgren J; Oberg G
Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
[TBL] [Abstract][Full Text] [Related]
36. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion.
Gan Y; Dai K; Zhang P; Tang T; Zhu Z; Lu J
Biomaterials; 2008 Oct; 29(29):3973-82. PubMed ID: 18639333
[TBL] [Abstract][Full Text] [Related]
37. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
38. Two steps to functional mesenchymal stromal cells for clinical application.
Bartmann C; Rohde E; Schallmoser K; Pürstner P; Lanzer G; Linkesch W; Strunk D
Transfusion; 2007 Aug; 47(8):1426-35. PubMed ID: 17655587
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis.
Zheng ZH; Li XY; Ding J; Jia JF; Zhu P
Rheumatology (Oxford); 2008 Jan; 47(1):22-30. PubMed ID: 18077486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
